PG

Progyny, Inc.

PGNYHealthcareNASDAQ

Healthcare Plans · Last scanned Jul 18, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$1.29B
+10.4% YoY
Net Income
$58.5M
+7.7% YoY
EBITDA
$90.2M
+27.7% YoY
Free Cash Flow
$200.2M

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11 RSI OverboughtRSI 89.3, above 70, stock may be overbought
Jul 10 RSI OverboughtRSI 92.3, above 70, stock may be overbought
About Progyny, Inc.

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. The company carries a $2.50B market cap, placing it firmly in the mid-cap category. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.

Key stats
Market Cap$2.50B
P/E (TTM)41.47
Fwd P/E14.21
EPS$0.77
Beta1.02
52W Change+45.1%
ROE14.9%
Analysis

The balance sheet looks solid with $225.1M in cash comfortably exceeding the $27.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $200.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 14.9% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 9.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $786.9M (2022) to $1.29B (2025), reflecting a 64% increase over the period.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Progyny, Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms